Archive for category: Disease

Information and news about disease category

, ,

Diagnostic Tampons: Fighting Cervical Cancer in Latin America

Cervical Cancer Latin AmericaCervical cancer represents one of the most pressing yet preventable crises in global health. It remains the fourth most common cancer among women worldwide, with 94% of deaths occurring in low- and middle-income countries, a stark testament to the role that inequality plays in who survives this disease. Indigenous women bear a disproportionate share of this burden, with some of the highest incidence rates concentrated in Central America.

Positively, vaccines for this disease are extremely effective, when administered at a young age HPV vaccine prevents infection, cervical cancer and other HPV-related disorders. The World Health Organization (WHO) has the goal to reduce the number of annual cases of cervical cancer to fewer than four per 100,000 women. Despite having such effective vaccines, a major issue lies with the accessibility and distribution of diagnostic tests and the subsequent intervention provision.

Cervical Cancer in Latin America

While the WHO’s elimination goal is ambitious, the reality for Latin America tells a different story – cervical cancer deaths in the region are projected to surpass 51,500 by 2030, with 89% of those occurring in Latin America and the Caribbean. Women across the region feel the burden. In El Salvador, 2.53 million women aged 15 and older are at risk of developing cervical cancer, representing a significant proportion of the country’s 6.3 million population.

The picture is similarly concerning in Guatemala, where 6.10 million women face the same risk out of a population of 18.6 million. Compounding this, HPV vaccination coverage in Guatemala stands at just 35%, with only 15% of individuals completing their final dose. El Salvador fares only marginally better at 43%, a figure that still falls well short of the WHO’s 90% target.

An example of how improved vaccination rates reduce prevalence and mortality together can be observed from Costa Rica. Here the Crude incidence rates sit at 14.4 for females with HPV-related cancers.

Prevention

A recurring challenge across the region is lack of awareness surrounding HPV, its link to cervical cancer, and the safety of available vaccines. In many indigenous and rural communities, misinformation and limited access to health education contribute to the low vaccination uptake seen in countries like Guatemala and El Salvador. Addressing this through community-led outreach and culturally sensitive health programs could be a foundational step towards closing the gap.

The Cervical Cancer Foundation works in collaboration with non-profits to lobby for legislative change and vitally provide health training to educate communities on the importance of HPV screening and available vaccines. Crucially, they provide cervical cancer prevention strategies within Latin America to aid in the reduction of this gap. With financial support from the Union of International Cancer Control, they aim to train more than 200 health educators from El Salvador to Costa Rica.

Screening

Yet even when education and vaccination efforts improve, a separate challenge remains: screening. The WHO’s elimination framework calls for screening of 70% of women with high-performance tests by the age of 35 and again by 45. In much of Latin America, this target is still far due to a shortage of trained gynaecologists, limited clinical infrastructure and the geographic remoteness of many at-risk communities. This is where an emerging technology may offer a meaningful solution- the diagnostic tampon.

A recent and applicable advancement for HPV has been analysed and assessed for usage in other LMIC’s. For example, in Tanzania, the use of diagnostic tampons has emerged as a promising, accurate method for cervical cancer screening. This reduces the need for trips to far or inaccessible hospitals for rural communities and those most at risk.

Studies comparing the accuracy of diagnostic tampons with clinician-collected samples for detecting HPV further corroborate this, demonstrating that use of diagnostic tampons has an overall accuracy of 95%, proving an easily implementable and highly specific screening tool.

Looking ahead

The diagnostic tampon is not a standalone solution. Eliminating cervical cancer in Latin America could require sustained investment across the entire health care system- from early education and vaccine distribution mechanisms to clinical infrastructure. However, this diagnostic tampon does represent significant advancements: practical and high-accuracy screening tools which meet women where they are rather than navigating systems which have historically excluded them. Thus, integrating this screening tool into existing public health frameworks, further backed by education, political will and adequate funding, offers a credible path towards turning the tide on one of the more preventable cancers.

– Juliette Dall’Aglio

Juliette is based in London, UK and focuses on Technology and Global Health for The Borgen Project.

Photo: Flickr

, ,

Improvement in the Treatment of TB in Kenya

TB in KenyaTuberculosis (TB) is a condition that mostly affects a person’s lungs but can also spread to other parts of the body. TB is caused by the bacterium Mycobacterium tuberculosis, which circulates through the air and spreads when inhaled. TB has been a persistent public health challenge in Kenya. According to the National Library of Medicine, TB is the fifth leading cause of death in the country. However, there has been a noticeable improvement in treating TB in Kenya. The director of the African region of the World Health Organization (WHO), Dr. Diallo Abdourahmane, stated that Kenya reduced TB cases by 41% and TB-related deaths by 60%. This progress is attributed to treatments such as preventive therapy, the BPaL regimen and digital adherence technologies.

Tuberculosis Preventive Treatment

One treatment used today is tuberculosis preventive treatment (TPT). Its goal is to prevent certain individuals from developing active TB by administering anti-tuberculosis medicine. The treatment destroys bacteria that have infected the body before they can harm organs or spread the illness. TPT specifically targets people living with human immunodeficiency virus (HIV). HIV weakens the body’s ability to fight infections, making individuals more vulnerable to TB. It is recommended for HIV patients to undergo this treatment to reduce the chance of developing TB. The preferred course consists of three months (3HP), during which the antibiotics isoniazid and rifapentine are taken once a week. However, this prescription may interact with other medicines, so each patient’s case should be considered individually.

BPaL Regimen

The BPaL regimen is a treatment course lasting six months. The WHO has recommended it as an alternative to lengthier treatments. The regimen combines four antibiotic medications: bedaquiline, pretomanid, linezolid and moxifloxacin. It targets drug-resistant TB, a form of the disease that does not respond to some standard medications. This treatment is primarily for adult patients and teenagers older than 14. Studies have shown a success rate of 89%, making it more effective than previous regimens.

Digital Adherence Technology

TB treatment outcomes have also improved with digital adherence technology (DAT). DAT refers to digital tools that use technological devices to record a patient’s daily medication information. Examples include smart pill boxes and medication sleeves. Researchers believe DAT motivates individuals with TB to take their daily medication consistently.

A 2026 study evaluated whether certain digital interventions improved TB treatment outcomes. The study found that digital platforms such as Keheala reduced the percentage of failed TB treatments, supporting the use of digital tools in TB care. DAT offers several benefits. Patients can choose the most suitable time to take their medication, fitting it into their routine. Patients can receive SMS reminders. Health care providers can access their patients’ information, allowing them to monitor consistency and identify patients who need additional support.

Looking Ahead

Although TB remains a serious issue in Kenya, the treatments discussed have demonstrated their effectiveness. Kenya has earned recognition from the WHO for its progress. The country has set further goals to reduce TB death rates by 90% and TB cases by 80% by 2030. Efforts in Kenya to reduce the impact of TB continue to show measurable results.

– Lara Ibrahim

Lara is based in Créteil, France and focuses on Technology and Global Health for The Borgen Project.

Photo: Flickr

, ,

Infectious Diseases in Morocco

Infectious Diseases in Morocco Infectious diseases in Morocco continue to be a major public health concern, especially in areas with limited access to health care and environmental challenges. Nonetheless, Morocco has achieved notable advancements in disease prevention through international partnerships, national health strategies and vaccination campaigns. These initiatives seek to strengthen the country’s health care system, reduce transmission and improve early diagnosis.

Tuberculosis Control Efforts

In Morocco, tuberculosis remains one of the most serious infectious diseases. Vulnerable populations with limited access to health care may be disproportionately affected by the illness, which spreads through airborne bacteria. The disease often affects poorer communities, where limited resources and health care access make prevention and treatment more difficult. This reinforces the importance of targeted public health interventions. Morocco has responded by putting in place a national tuberculosis control program that emphasizes early detection, free treatment and enhanced surveillance systems.

To encourage early testing and treatment, health authorities have increased diagnostic services and launched public awareness campaigns. These programs have helped Morocco reduce transmission in numerous communities and maintain comparatively high treatment success rates.

Addressing Leishmaniasis

Another infectious disease affecting Morocco is leishmaniasis, which spreads through sandflies in rural areas. The most prevalent type of leishmaniasis in the country is cutaneous leishmaniasis, which results in skin lesions. In some areas, outbreaks may occur due to both population movement and environmental factors.

Morocco has strengthened surveillance systems and implemented vector control programs to combat the disease. Public health officials also aim to inform communities about early detection and prevention strategies to reduce the severity and spread of infections.

Hepatitis Prevention and Treatment

Viral hepatitis is also a significant health challenge. Prevention and early diagnosis are crucial because untreated hepatitis B and C infections can result in chronic liver disease. As part of wider national health strategies, Morocco has expanded vaccination coverage and screening programs.

Treatment access and disease monitoring are supported by international partnerships and public health initiatives. Increased awareness and vaccination efforts are helping reduce the long-term impact of hepatitis and strengthen overall disease prevention measures.

Public Health Progress and Prevention

Morocco has shown that consistent public health investment can lower the risks of infectious diseases despite ongoing challenges. After decades of prevention efforts, the country eliminated malaria in 2014, demonstrating the effectiveness of coordinated national health policies and surveillance programs.

In Morocco, prevention, education and improved access to health care are becoming increasingly important aspects of addressing infectious diseases. The country continues to work toward better public health outcomes and healthier communities through strengthened disease monitoring systems and expanded treatment programs.

– Honey Regev

Honey is based in Edinburgh, Scotland and focuses on Global Health for The Borgen Project.

Photo: Flickr

, ,

Eliminating Trachoma in the Most Impoverished Communities

TrachomaTrachoma is an infectious eye disease caused by the bacterium Chlamydia trachomatis. It is a chronic form of conjunctivitis and causes 1.4% of global blindness, yet governments can completely prevent it. Thirty countries across Africa, Asia, Central and South America, the Middle East and Australia have faced trachoma as a public health problem. It affects the most impoverished parts of the world. 

Infection spreads easily due to poor hygiene, crowded housing and limited access to sanitation and water. Viral disease and poverty fuel this spread, making people vulnerable to preventable diseases such as trachoma.

Eliminating Trachoma in Libya

On February 18, 2026, the World Health Organization (WHO) celebrated Libya’s elimination of trachoma. Libya struggled with trachoma for more than a century, but hard work and commitment led to this recent success. The country’s victory over trachoma shows how supporting the fight against neglected tropical diseases can help millions over time.

Political unrest and displacement in Libya limited access to quality health care, yet the country still managed to eliminate trachoma. Displacement and such unrest drive poverty by increasing the demand for water, sanitation and hygiene services. This connection between disease and poverty makes eliminating trachoma even more significant.

The SAFE Initiative

Countries affected by trachoma adopted the Surgery, Antibiotics, Facial cleanliness and Environmental improvement (SAFE) strategy. Through this effort, Pfizer and the International Trachoma Initiative (ITI) have delivered more than one billion doses of Zithromax to countries in need. Experts now estimate that trachoma could be eliminated as a public health threat worldwide by 2030.

ITI, a U.S.-based nonprofit, currently operates in more than 14 countries across Southeast Asia and Africa. These interventions address the link between disease and poverty and have improved the lives of millions. Twenty-seven additional countries, including Papua New Guinea and Pakistan have also eliminated trachoma, underscoring the importance of tracking its prevalence and taking decisive action against infectious diseases. 

Fewer than 100 million people now require treatment, a historic global low since the WHO began recording cases. This milestone reinforces the need to confront disease alongside poverty. It demonstrates how strong local leadership, backed by international coordination, can improve the well-being of the world’s poorest populations.

Final Remarks

The massive success of the trachoma eradication campaign demonstrates the positive impact international help can have on many other tropical diseases. Research into trachoma has taught researchers much about how to slow its spread. Making hygiene a game for young children helps them avoid touching their eyes and mouths, which, in turn, helps women, who often act as primary caregivers. 

Additionally, communities can use the structures built for trachoma to fight other diseases. If people around the world work together to combat disease and poverty, everyone’s well-being will improve.

– Caitlin Cooper

Caitlin is based in Aberdeen, UK and focuses on Global Health and Politics for The Borgen Project.

Photo: Flickr

, ,

Saving Lives: Malaria Prevention in Sub-Saharan Africa

Malaria Prevention in Sub-Saharan AfricaMalaria prevention in sub-Saharan Africa remains a critical global health priority. Despite significant progress over the past two decades, malaria continues to affect countries across the region disproportionately. Expanding prevention efforts is essential to saving lives, strengthening economies and reducing poverty.

The Scale of the Problem

According to the World Health Organization (WHO), there were approximately 282 million malaria cases globally in 2024, with sub-Saharan Africa accounting for about 95% of cases and deaths. The region recorded more than 600,000 malaria-related deaths, with children under 5 representing about 76% of those fatalities. Countries such as Nigeria, the Democratic Republic of the Congo, Uganda and Mozambique carry some of the heaviest burdens.

Rural communities are especially vulnerable due to limited access to health care facilities and preventive tools.

Impact on Education and Economic Stability

Malaria prevention in sub-Saharan Africa is not only a health issue but also an economic one. Frequent illness leads to missed school days for children and lost wages for adults. In high-transmission areas, students may miss several weeks of school each year due to illness or caring for sick family members. Repeated absences can reduce academic performance and long-term educational outcomes.

For adults, malaria decreases workforce productivity. Farmers may be unable to tend crops during peak agricultural seasons and small business owners may lose income due to illness. Health care costs, transportation to clinics and lost workdays push many households deeper into poverty.

In some communities, families must borrow money or sell assets to pay for treatment, creating long-term financial strain. Fortunately, significant progress has been made through coordinated prevention strategies. Insecticide-treated nets (ITNs), indoor residual spraying and rapid diagnostic testing have helped reduce transmission rates in many countries.

Recently, malaria vaccines have also been introduced in select African nations, offering additional protection for young children.

Organizations Combating Malaria in Sub-Saharan Africa

  • The Global Fund: It provides funding to countries to strengthen prevention, treatment and health systems. Since its founding, the Global Fund has supported the distribution of hundreds of millions of ITNs and funded malaria treatment programs across dozens of African countries. In 2024 alone, the organization distributed more than 160 million mosquito nets worldwide.
  • UNICEF: This nonprofit works closely with governments to protect children from malaria. The organization supports seasonal malaria prevention programs, distributes bed nets and improves access to testing and treatment in remote areas. UNICEF has helped deliver millions of doses of preventive medicine to children in high-risk countries such as Nigeria and Chad.
  • The President’s Malaria Initiative: This Initiative operates in more than 20 African countries. It supports indoor spraying campaigns, distributes millions of bed nets annually and strengthens local health systems. The Initiative has contributed to significant reductions in malaria mortality rates in several partner countries since its launch.

Final Remarks

Malaria prevention in sub-Saharan Africa is directly linked to poverty reduction, educational advancement and economic stability. By protecting vulnerable populations, especially young children, these efforts help communities build healthier and more productive futures. Continued global commitment and coordinated action are necessary to reduce malaria cases further and move closer to elimination.

– Nishanth Pothapragada

Nishanth is based in London, Ontario, Canada and focuses on Global Health for The Borgen Project.

Photo: Flickr

, ,

Tackling NTDs in Fiji

NTDs in FijiFiji is an archipelago situated in the South Pacific, with a small population of just under 1 million. The World Health Organization (WHO) has declared all Pacific countries particularly vulnerable to the spread of infectious diseases and natural disasters due to the acute effects of climate change in the region. Neglected Tropical Diseases (NTDs) are an umbrella group of more than 20 infectious conditions most commonly affecting poorer populations in tropical regions.

NTDs have a far-reaching impact on the communities where they circulate, often carrying a poor prognosis and leading to disfigurement or death. Beyond the severe physical implications, NTDs are associated with social exclusion and cycles of poverty stemming from the poor health of the infected individual. However, with effective management and coordination strategies, the impact of NTDs can be significantly reduced. Through sustained effort from both a social and medical perspective, Fiji has seen several landmark successes in its fight against NTDs. Below are three examples of progress in the fight against NTDs in Fiji.

Elimination of Trachoma

Trachoma is the leading infectious cause of blindness in the world and is spread by direct contact with infected individuals. The overall number of people at risk of contracting trachoma due to residence in an endemic region has more than halved between 2010 and 2024, due to improved data collection and the successful implementation of the WHO’s reduction strategy. In 2025, Fiji eliminated trachoma as a public health problem. This made it the first Neglected Tropical Disease in the country to achieve this status, as granted by the WHO.

The WHO attributed the elimination to extensive testing, public health initiatives and awareness efforts. The elimination of the disease marks a turning point in a country where trachoma had at several points been a public health concern, notably during a resurgence in the 2000s.

National Response to Scabies

Scabies is a highly infectious disease that is particularly prevalent in impoverished communities in tropical areas. It can lead to severe illness, including heart disease and kidney disease.

Scabies has historically been prevalent in Fiji. In 2016, the government found that skin and soft tissue infections, of which scabies is a part, were the fifth-highest cause of death in the country. Faced with this challenge, Fiji carried out a national scabies audit and subsequently embarked on a program of mass drug administration (MDA).

Fiji was one of the first two countries in the world to implement MDA for scabies. One study showed that the program significantly reduced community prevalence of scabies within a year, from 32% to 2%. The campaign was successful in reducing the prevalence of the NTD to a controllable level, marking a significant achievement for national disease prevention efforts.

Lymphatic Filariasis

Lymphatic filariasis is a Neglected Tropical Disease spread by infected mosquitoes that causes abnormal swelling. It is commonly found in low-income communities where access to health care and sanitation is limited. Although it has faced several challenges in the effective control of lymphatic filariasis, Fiji has made and continues to make progress in tackling the disease. Between 1997 and 2007, Fiji significantly reduced the presence of the NTD, partly due to successful mass drug administration. The mass drug administration program is still underway, with coverage having reached more than 94% of the population, and transmission of the disease among at-risk populations having dropped by 43%.

Looking Ahead

Neglected Tropical Diseases remain a significant global health priority, especially among impoverished communities in tropical areas. However, Fiji has demonstrated how public health measures, community engagement and awareness efforts can contribute to reducing, and in some cases eliminating, NTDs.

– Phoebe Lang-Clapp

Phoebe is based in Montréal, Canada and focuses on Global Health for The Borgen Project.

Photo: Flickr

, ,

Poverty and Malaria Vaccine Price Cuts

Poverty and MalariaMalaria remains one the world’s deadliest diseases, disproportionately affecting children in Africa. Global health organizations achieved a major breakthrough in the fight against this life-threatening infection in 2023 by rolling out the world’s first malaria vaccine: manufacturers have now slashed the price of this vaccine, along with a second approved vaccine, and it could be an important step in relieving the socioeconomic burden of the disease across the African continent.

In late 2025, Gavi, the Vaccine Alliance, and children’s agency UNICEF struck a pricing deal to cut the cost of the R21/Matrix-M vaccine to $2.99 USD from around $4. Analysts project that these reductions will unlock 30 million extra doses before 2030, protecting around 7 million children. This monumental pricing deal follows on from another cost reduction that Bharat Biotech and GSK announced in June of 2025, stating that they will progressively reduce the price of the RTS,S malaria vaccine by half, falling to less than $5 USD per dose.

A Crucial Vaccination Effort

Researchers initially struggled to develop an effective malaria vaccine: vaccines train the immune system to recognize proteins on the surfaces of infectious agents (e.g., bacteria, viruses). The infectious agent associated with malaria is Plasmodium falciparum, a parasite that can evade the immune system and change its surface proteins throughout its life cycle, thus finding a suitable vaccine to target the parasite became complicated.

When researchers achieved clinical breakthroughs in 2004 and refined a vaccine formula, it was time to move to human trials. The newly-named ‘RTS,S/AS01’ vaccine was administered to groups of young children across sub-Saharan Africa in the first rounds of human testing.

Trials ran from 2004 until 2015 and concluded that three doses of RTS,S was enough to reduce clinical malaria cases in children by up to 39%. In January 2024, a mass roll-out of the RTS,S vaccine began in Cameroon and authorities soon followed it with the distribution of the more cost-effective vaccine, R21/Matrix-M. Now, RTS,S and R21 vaccinations form part of routine childhood immunizations in more than 20 African countries, acting as a crucial tool for protecting children against deadly infections.

The Importance of Equitable Pricing in Immunization

Many factors influence the pricing of a vaccine introduced into the market, including patent protection, production cost and volume of contract. Notably, there is a positive correlation between a country’s Gross National Income (GNI) and the price point at which suppliers sell a dosage within the country- this is known as tiered pricing.

Rather than selling a vaccine at a flat rate, pharmaceutical companies use tiered pricing to charge high-income countries a higher price per dosage to balance affordability in lower-income markets, cover research and development (R&D) costs and generate profit. This improves the accessibility of vaccines regardless of geographical location and socioeconomic status.

However, malaria is a disease that primarily affects the Global South, therefore the market for the RTS,S and R21 vaccines for high-income countries in the Global North was almost non-existent. The typical vaccine development model and tiered pricing system could not be implemented, and external organizations, including the World Health Organization (WHO) and The Bill and Melinda Gates Foundation, filled the funding gaps.

The introduction of the second-ever malaria vaccine, R21, improved vaccine equity through accessibility: the formula has a lower concentration of antigens (the active ingredient in vaccines) whilst maintaining its efficacy, which drastically cuts manufacturing costs. Doses of R21 are better adapted to the African climate because of less strict requirements in cold chain storage and transport, reducing accidental wastage and ensuring more children receive protective immunization.

The Socioeconomic Impact of Immunity

The relationship between malaria and socioeconomic status can be considered bi-directional: malaria infection and recovery minimizes a person’s ability to work, attend school or perform caregiving duties, increasing the risk of experiencing poverty. Conversely, those living in poor conditions without access to adequate sanitation or health care face a higher risk of malaria infection and suffering more severe disease outcomes.

Therefore, immunity can break the cycle of poverty and malaria. As a whole, every $1 USD spent on vaccines saves between $16-44 USD on treatments and broader economic implications of disease. Driving down the price of each dose improves vaccine equity, ensuring that communities most affected by extreme poverty and seasonal malaria spikes will be among those protected.

However, immunization alone is not enough to decrease the malaria burden across the African continent. Research from Gavi, the Vaccine Alliance, demonstrates that the RTS,S vaccine is around 63% effective as a prevention tool, but when used in combination with insecticide-treated bed nets, indoor residual spraying and seasonal malaria chemoprevention (SMC), efficacy rises to 93%. Studies have shown that the malaria vaccine is least effective in children who come from low socioeconomic status households, this is likely due to a lack of health care access which prevents children from completing all three immunizations along with preventative SMC treatments.

What Will the Future of Malaria Vaccination Look Like?

More and more African countries are adopting affordable malaria vaccine strategies, and keeping this momentum will be the key to imagining a malaria-free future. Community engagement has proven to be a highly successful strategy in effort to relieve concerns regarding the vaccine’s safety and cost. In the early stages of vaccine roll-out in Cameroon, parents initially responded to the scheme with hesitancy: community and religious leaders drove up vaccine demand by encouraging open discussions at community meetings and disseminating misinformation. Following the success of Cameroon’s vaccination campaign, global health partners have adopted this person-led strategy by connecting with community leaders and technical experts directly.

Gavi has predicted that immunizing around 50 million children against malaria before 2030 could save more than 170,000 lives. An increasing number of children will have the opportunity to complete their education uninterrupted by disease and parents will be relieved of the costly burdens of caregiving and clinical treatments. African governments and communities have responded to the agreement to slash malaria vaccine prices with great optimism and will be a huge step in protecting the most vulnerable populations from poverty.

– Charlotte Bunn

Charlotte is based in Bristol, UK and focuses on Good News and Global Health for The Borgen Project.

Photo: Flickr

, ,

Melioidosis in Bangladesh Threatens Rural Communities

Melioidosis in BangladeshHidden beneath flooded rice fields and carried by monsoon rains, a little-known disease is shaping a quiet public health crisis. Melioidosis in Bangladesh exists at the intersection of climate, poverty and limited health care access. Yet it remains largely invisible in national disease statistics.

For many patients, the illness never earns its real name, instead slipping through the health care system disguised as more familiar conditions. Rural communities suffer the most severe consequences, as their livelihoods depend on daily contact with soil and water. Understanding why melioidosis continues to evade recognition is essential not only to saving lives but also to protecting the people who sustain Bangladesh’s economy and food security.

Misdiagnosed, Misrepresented and Misunderstood

Melioidosis manifests differently from person to person and can range in severity from flu-like symptoms to skin abscesses and sepsis. Burkholderia pseudomallei enters the body through ingestion, inhalation or skin cuts, allowing it to infect the bloodstream, lungs and skin, sometimes simultaneously. Because the bacteria can affect multiple organ systems, melioidosis is often misdiagnosed as tuberculosis, fungal infections or even cancer.

These misdiagnoses can delay treatment, even though antibiotics must be started promptly and completed fully to improve recovery outcomes. Since the ’60s, hospitals in Bangladesh have reported only around 100 cases of melioidosis. This figure is widely believed to underestimate the true burden of the disease.

One study estimates that melioidosis in Bangladesh could account for up to 17,000 cases and 9,500 deaths each year. This gap is mainly due to limited clinical awareness and insufficient laboratory capacity for proper diagnosis. Patients with other underlying conditions, known as comorbidities, are at a higher risk of melioidosis, including those with diabetes, alcohol use disorder and chronic lung disease, which may complicate diagnosis further.

Rural Communities in Bangladesh at High Risk

Burkholderia pseudomallei is well-adapted to Bangladesh’s warm, humid climate. The bacterium thrives in environments with year-round high temperatures, waterlogged soil and frequent monsoon rainfall. As a result, rural communities, particularly those dependent on agriculture, face the greatest risk of infection.

Agriculture accounts for nearly 90% of rural employment and many farmers work barefoot or without protective equipment, increasing their exposure through direct contact with contaminated soil and water. Social factors further compound the risk. Poverty rates in rural Bangladesh stand at around 20%, compared with 16.5% in urban areas.

Illness caused by melioidosis can prevent individuals from working, deepening economic hardship for affected families and communities. Looking more broadly, the agricultural sector is one of the most productive in Bangladesh’s economy, contributing around 11% of the national GDP. Rural farming communities sit at the heart of this system.

Yet, they often have the least access to health care due to geographic and financial constraints. Protecting farmers and their families from melioidosis, therefore, supports not only their health and livelihoods but also the country’s food security and export capacity. This underscores the need for adequate protective equipment and timely access to effective antibiotic treatment.

Fighting for Futures: The South Asian Melioidosis Congress

In 2023, the third South Asian Melioidosis Congress (SAMC) met in Dhaka, Bangladesh, to discuss emerging research concerning the tropical disease and to share methods of its detection and management. These educational meetings aimed to raise awareness of melioidosis and provide physicians with the tools for accurate diagnosis. This proved successful, with nine reported cases of melioidosis in Bangladesh soon after the SAMC’s conclusion, each patient with different symptoms.

This reflects the vigilance of health care professionals regarding the early diagnosis of melioidosis as empowered by the collective effort of the SAMC to fight this disease. Following the conclusion of the fourth SAMC at the end of 2025, organizers are hopeful that renewed awareness will lead to more diagnosed cases being reported in Bangladesh. The theme of the fourth SAMC, “Melioidosis: The Great Mimicker,” highlighted the disease’s ability to mimic a wide range of illnesses.

The most recent congress brought together experts from across the world in Northeast India to discuss key issues surrounding melioidosis, including diagnostic approaches, public health implications and treatment guidelines. These discussions aimed to raise awareness of the disease and strengthen future efforts to protect vulnerable rural communities.

– Charlotte Bunn

Charlotte is based in Bristol, UK and focuses on Global Health for The Borgen Project.

Photo: Flickr

, ,

5 Diseases Impacting Myanmar

Diseases Impacting MyanmarMyanmar is a nation of more than 100 ethnic groups, yet the Rohingya genocide has brought attention to the country’s corrupt military takeover from 2021. Due to the poor living conditions in the country and the current climate crisis, the diseases impacting Myanmar run rampant, but these are not just medical problems. They are symptoms of a broken health care system that conflict, repression, displacement and underfunding have weakened. However, the combined effort of international aid and volunteering has allowed some solutions to this health crisis. Here is information about five diseases that are impacting Myanmar.

5 Diseases Impacting Myanmar

The communicable diseases impacting Myanmar include:

  • Tuberculosis: The incidence rate of TB was 558 per 100,000 population in 2023 and close to 50,000 deaths are as a result of the disease in Myanmar. Treatment interruptions have increased drug-resistant TB, yet NGOs are still using community-based treatment. More than 3.5 million internally displaced people and worsening poverty have increased TB vulnerability. In 2024, Doctors Without Borders helped 480 people start treatment for TB, with 981 staff in Myanmar providing health care services.
  • Malaria: In 2023, there were 229,000 cases of malaria in Myanmar. Cases are resurging in conflict areas, despite proven interventions such as bed-net distribution, rapid testing and cross-border health programs. However, Myanmar aims to eliminate the transmission of malaria cases by 2030, and 126,562 patients received treatment between January and August 2025, according to Deputy Minister for Health, Professor Dr Aye Tun. 
  • HIV/AIDS: Disrupted access to antiretroviral therapy places lives at risk, even though mobile clinics have proven effective. In 2023, 0.9% of people aged between 15 and 49 suffered from HIV, with 5,800 of them dying. These diseases are not just affecting older people, but children and young adults, as well as people in detention.
  • Dengue Fever: Rising infections linked to poor sanitation highlight the need for investment in water, waste management and disease surveillance. Myanmar is a country with frequent and continuous risk of dengue, especially due to seasonal changes. In 2019, dengue fever mostly infects children aged between 5 and 9 years old with 4,473 cases registered. The Ministry of Health tries to combat dengue by killing mosquito larvae, then fogging houses near patients to eliminate mosquitoes.
  • Cholera/Diarrheal Diseases: Cholera is a waterborne disease that has surged in at least nine states in Myanmar since 2024. Around 300 people reported suffering from a cholera outbreak in late 2025, with seven confirmed dead. These people include vulnerable children without safe water or living conditions. Emergency WASH (Water, Sanitation and Hygiene) interventions that international donors support can address conditions.

Chronic Illnesses

Chronic illnesses such as diabetes, hypertension, heart disease and cancer are fatal for these people, because hospitals are underfunded, medicines are unavailable and travel to care is dangerous. Expanding access to health care, essential medicines lists and decentralized treatment is critical. Myanmar remains one of the world’s most underfunded humanitarian operations, receiving less than $136 million in 2025 of the $1.1 billion it needs.

The Relationship Between Poverty and Disease in Myanmar

In developing countries like Myanmar, preventative medicines and measures can be obtained by the wealthy, but this means that often, families without enough money face higher risks of dying from avoidable disease. Whilst in developed countries, the elderly are more likely to face these diseases, in Myanmar, people younger than the age of 70, and even children are suffering from both communicable and non-communicable diseases, due to the disparity between the country’s rich and the poor. Nearly 32% of the country lives in poverty. Poverty and disease in Myanmar share a symbiotic relationship, especially considering that after the 2025 earthquake, many people are living in tents, allowing outbreaks of cholera and other waterborne diseases to occur.

Solutions

There have been developments however. The Republic of Korea made a generous contribution to UNICEF to help families and the vulnerable in Myanmar, especially considering that one-third of more than 3.5 million displaced are children.

Organizations like Doctors Without Borders are trying their best to support Myanmar’s health care. Following the 2025 earthquake, it has restored more than 200 bore holes, supplied hospital beds and been trying to aid victims of serious diseases. Following the 2021 military coup, Doctors Without Borders donated medical supplies to Yangon and other locations. The success of help like this is demonstrated in the case of Ko Tin Maung Shwe, a patient suffering from HIV and hepatitis C. With hospitals being destroyed and the fear of travelling, Doctors Without Borders are helping patients like him with blood tests, consultations and medication. As well as this, it is expanding access to psychosocial support.

All of this help is essential because the ongoing conflict in Myanmar by the military regime has damaged civilian infrastructure and in 2023 alone, more than 418 attacks on health care had occurred. Alongside the violence, the climate crisis that has caused major earthquakes in Myanmar has led to an increase in the number of vulnerable people suffering from disease.

How Is the World Aiding Myanmar?

In 2025, the U.K. announced additional humanitarian funding to provide health care to 1 million people across Myanmar. The then Minister for Development, Anneliese Dodds, underscored this commitment by stressing that the U.K. would not abandon the people enduring a brutal conflict – one that has fueled a humanitarian emergency in a country already exposed to the impacts of changing weather patterns. This assistance has extended beyond the Rohingya community, supporting vulnerable populations nationwide, particularly in the aftermath of the 2025 Myanmar earthquake. Despite this, Donald Trump’s USAID cuts have severely limited the amount of health care support that exists, but countries within the EU, as well as NGOs like UNICEF, are still trying to help the crisis in Myanmar. UN agencies are committed to helping affected populations in Myanmar, proven by the fact that in July 2025, nearly 306,000 people across 59 earthquake-hit townships received health services.

Looking Ahead

People in Myanmar are in desperate need of humanitarian aid. They are not just suffering from war injuries, but they are also dying from illnesses that the international community already knows how to treat. The diseases impacting Myanmar are more than humanitarian crises, they are symbols of injustice, repression and perhaps even hope – hope that once the world understands how much the vulnerable people need help, they will act.

– Anisa Begum

Anisa is based in Birmingham, UK and focuses on Global Health for The Borgen Project.

Photo: Unsplash

, ,

Diseases Impacting Libya: Top 3 Factors Affecting Health Care

Diseases Impacting LibyaLocated in the north of Africa between Algeria and Egypt, Libya has a population of about 7.5 million people, most of them concentrated in urban, coastal cities like Tripoli and Benghazi. The World Health Organization (WHO) identified cholera and polio as very high risk diseases to impact Libyans in 2025. Other non-communicable diseases such as cancer are also threatening many individuals because of how expensive and difficult it is to get treatment. Here are the top three factors affecting health and safety, including access to health care and diseases impacting Libya.

1. Climate and Changing Weather Patterns

Libya is one of the world’s most arid countries. It witnesses periods of extreme heat, droughts and violent rain and dust storms. These acute weather conditions compromise health and safety, as access to potable water becomes more scarce and food insecurity spikes.

In September 2023, cyclone Daniel made a bad situation worse in terms of diseases impacting Libya, with flooding and damages to already deteriorating infrastructure including health and care facilities in Derna. Water contamination and lack of sanitation were top reasons for health concerns as storms also destroyed two dams upstream of the city. In the immediate aftermath of the storm, medical professionals were most concerned about potential cholera and acute watery diarrhea (AWD) outbreaks. As of October 3, 2023, the National Center for Disease Control (NCDC) reported 1,905 cases of AWD.

2. Sudanese Migration 

A war-torn Sudan has led many to flee and seek refuge in its neighboring countries. Since April 2023, cities like Al Kufra in Eastern Libya saw an influx of somewhere close to 500 Sudanese migrants passing through each day. Such a high number of refugees has led to issues like overcrowding, especially in settlements, which in turn could lead to an increase in diseases impacting Libya. 

Those arriving from conflict zones are often in ill-health. Be it communicable diseases or in poor mental-health, many have not had access to vaccinations or other preventative treatments that could avoid medical emergencies like outbreaks. Officials like WHO are most concerned about a cholera epidemic, though tracking its spread will prove difficult for lack of testing facilities and resources.

3. The Government

Since the 2011 Revolution, Libyans have witnessed waves of political fragmentation, tension and violence. The persistent conflict caused years of neglect in the health care system, ultimately resulting in inconsistent health care services for Libyans.

Opposing governments and factions fighting for power have divided the country, making it difficult, if not impossible, to coordinate with health care professionals and NGOs on the ground to establish clinical practice guidelines that would prevent outbreaks and efficiently combat diseases impacting Libya. 

Then, in April 2025 the Internal Security Agency (ISA) based in Tripoli announced the shutdown of headquarters of 10 major NGOs, including MSF, for compromising Libya’s social demographic and for promoting values that go against Libyan identity. MSF reported at least six known casualties in the weeks since it had to pull its aid, and expect the order to have more consequences on their patients that they will not be able to track due to loss of contact.  

Who’s Helping?

After Cyclone Daniel, organizations such as UNICEF, the Red Cross, the World Food Programme (WFP) and the International Medical Corps (IMC) sent immediate relief. This included, for example, renovating 25 health facilities, training more than 1,100 health care providers and distributing food to more than 15,000 people. 

Though the 10 humanitarian organizations ordered to leave Libya in April 2025 have not been allowed to return to date, there are still other groups present in the country. The International Medical Corps (IMC), for example, provided more than 27,000 medical consultations and helped countless refugees back on their feet as of July 2025. The European Union (EU) continues to fund aid in correspondence with WHO, Première Urgence Internationale and the IMC. In 2025, the EU funded €3 million in response to mass Sudanese migration. 

Given the inconsistency in health care provisions, NGOs on the ground are doing significant work for Libyans and refugees. There is still much work to do. Providing medical aid and investing in care facilities is just scratching the surface. Without addressing the climate crisis, the lack of accommodation for refugees and government fragmentation, health and safety will remain compromised and diseases impacting Libyans will continue to risk lives. 

– Brittany Buscio

Brittany is based in Montreal, Canada and focuses on Good News and Global Health for The Borgen Project.

Photo: Flickr